Antoine Ferry
Directeur Général chez Laboratoires C.T.R.S. SAS
Profil
Antoine Ferry is currently the Chairman & Chief Executive Officer at Laboratoires C.T.R.S.
SAS.
He is also the Director & Chief Medical Officer at Gene Signal International SA, starting in 2010.
Additionally, he holds the position of Director at Aterovax SA since 2007.
Dr. Ferry is the President of Hesperus AD, starting in 2014.
Previously, he served as the Chairman-Supervisory Board at Theraptosis SA.
Postes actifs de Antoine Ferry
| Sociétés | Poste | Début |
|---|---|---|
Gene Signal International SA
 Gene Signal International SA Pharmaceuticals: MajorHealth Technology Gene Signal International SA engages in the development of drugs to manage angiogenesis based conditions. It is a research based biotechnology company specialized in the discovery, development, and commercialization of a new class of oligonucleotides, proteins and monoclonal antibodies to treat a range of conditions where angiogenesis plays a determinant role. The company was founded by Eric Viaud, Salman Al-Mahmood, and Eric Thorin in 2000 and is headquartered in Lausanne, Switzerland. | Directeur Technique/Scientifique/R&D | - |
Aterovax SA
 Aterovax SA Medical/Nursing ServicesHealth Services Aterovax SA develops in vitro diagnostic products for the management and assessment of cardiovascular diseases. Its products include diagnostic blood tests for determining and measuring activity of the cardiovascular biomarkers secretory phospholipase A2 (sPLA2) and secretory phospholipase A2-IIA (sPLA2-IIA) which provide physicians clinical information about the presence of a destabilized atherosclerotic plaque. The company was founded by Alain Tedgui, Ziad Mallat, Philippe Gabriel Steg, Joelle Benessiano and Jean-Marie Freyssinet on June 29, 2006 and is headquartered in Paris, France. | Directeur/Membre du Conseil | 01/02/2007 |
Laboratoires C.T.R.S. SAS
 Laboratoires C.T.R.S. SAS Pharmaceuticals: MajorHealth Technology Laboratoires C.T.R.S. SAS is a French pharmaceutical company that manufactures pharmaceutical products. The company is based in Boulogne-Billancourt, France. The company was founded in 2002 by Bernard Deschamps. The CEO is Antoine Ferry. | Directeur Général | - |
| Hesperus AD | President | 22/01/2014 |
Anciens postes connus de Antoine Ferry
| Sociétés | Poste | Fin |
|---|---|---|
Theraptosis SA
 Theraptosis SA Pharmaceuticals: MajorHealth Technology Theraptosis S.A. , a biotechnology company, was founded in April 2001. Theraptosis designs and develops various drugs that act on key apoptosis regulators to fight diseases associated with lack or excess of apoptosis including cancer and neurodegenerative diseases. The Company's key assets include a dual technology platform (CytoTrust™ and MitoTrust™) for screening and targeting purposes and a pipeline of products in the areas of CNS and oncology. Theraptosis' discovery engines integrate mitochondria, and apoptosis expertise, and has developed pre-clinical animal models. | Président | 10/03/2010 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Theraptosis SA
Theraptosis SA Pharmaceuticals: MajorHealth Technology Theraptosis S.A. , a biotechnology company, was founded in April 2001. Theraptosis designs and develops various drugs that act on key apoptosis regulators to fight diseases associated with lack or excess of apoptosis including cancer and neurodegenerative diseases. The Company's key assets include a dual technology platform (CytoTrust™ and MitoTrust™) for screening and targeting purposes and a pipeline of products in the areas of CNS and oncology. Theraptosis' discovery engines integrate mitochondria, and apoptosis expertise, and has developed pre-clinical animal models. | Health Technology |
Gene Signal International SA
Gene Signal International SA Pharmaceuticals: MajorHealth Technology Gene Signal International SA engages in the development of drugs to manage angiogenesis based conditions. It is a research based biotechnology company specialized in the discovery, development, and commercialization of a new class of oligonucleotides, proteins and monoclonal antibodies to treat a range of conditions where angiogenesis plays a determinant role. The company was founded by Eric Viaud, Salman Al-Mahmood, and Eric Thorin in 2000 and is headquartered in Lausanne, Switzerland. | Health Technology |
Aterovax SA
Aterovax SA Medical/Nursing ServicesHealth Services Aterovax SA develops in vitro diagnostic products for the management and assessment of cardiovascular diseases. Its products include diagnostic blood tests for determining and measuring activity of the cardiovascular biomarkers secretory phospholipase A2 (sPLA2) and secretory phospholipase A2-IIA (sPLA2-IIA) which provide physicians clinical information about the presence of a destabilized atherosclerotic plaque. The company was founded by Alain Tedgui, Ziad Mallat, Philippe Gabriel Steg, Joelle Benessiano and Jean-Marie Freyssinet on June 29, 2006 and is headquartered in Paris, France. | Health Services |
Laboratoires C.T.R.S. SAS
Laboratoires C.T.R.S. SAS Pharmaceuticals: MajorHealth Technology Laboratoires C.T.R.S. SAS is a French pharmaceutical company that manufactures pharmaceutical products. The company is based in Boulogne-Billancourt, France. The company was founded in 2002 by Bernard Deschamps. The CEO is Antoine Ferry. | Health Technology |
| Hesperus AD |